BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to fight cancer. Get up to date with the BeiGene hematology pipeline and clinical trials.
Slide kit outlining a new therapeutic approach for previously untreated chronic lymphocytic leukemia (CLL)
Slide kit describing the effectiveness of using a BTKi in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).
Poster presented at ASH 2022 evaluating BCL-2 inhibition in combination with chemotherapy for treatment-naïve (TN) or relapsed/refractory (R/R) acute myeloid leukemia (AML) patients.
Poster presented at ASH 2022 evaluating BTKi treatment for relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients.